Mechanisms of cell death and proliferation of aldosterone-producing adenoma

doi:10.16352/j.issn.1001-6325.2024.06.0758

Abstract

Abstract: Aldosterone-producing adenoma (APA) is one of the main causes of primary aldosteronism (PA). Current researches on its autonomous secretion of aldosterone mainly focus on the detection of somatic driver genetic mutations. However, the specific mechanisms underlying the death and proliferation of adrenal cortical cells and the occurrence and development of adenomas are still unclear. This study aims to review the research progress on the mechanisms of cell death and proliferation of APA by combining previously published studies on genomics, transcriptomics, metabolomics, and epigenetics related to adrenal tissues.

Key words: primary aldosteronism, aldosterone-producing adenoma, cell proliferation and apoptosis, signaling pathway, multi-omics study

CLC Number:

R586.9

GAO Yinjie, TONG Anli. Mechanisms of cell death and proliferation of aldosterone-producing adenoma[J]. Basic & Clinical Medicine, 2024, 44(6): 758-762.

References 25

[1]	Mulatero P, Monticone S, Deinum J, et al. Genetics, prevalence, screening and confirmation of primary aldosteronism: a position statement and consensus of the working group on Endocrine Hypertension of The European Society of Hypertension[J]. J Hypertens, 2020, 38:1919-1928.
[2]	Nanba K, Baker JE, Blinder AR, et al. Histopathology and genetic causes of primary aldosteronism in young adults[J]. J Clin Endocrinol Metab, 2022, 107:2473-2482.
[3]	Pitsava G, Faucz FR, Stratakis CA, et al. Update on the genetics of primary aldosteronism and aldosterone-produc-ing adenomas[J]. Curr Cardiol Rep, 2022, 24:1189-1195.
[4]	Yang Y, Gomez-Sanchez CE, Jaquin D, et al. Primary aldosteronism: KCNJ5 mutations and adrenocortical cell growth[J]. Hypertension, 2019, 74:809-816.
[5]	Monticone S, Hattangady NG, Nishimoto K, et al. Effect of KCNJ5 mutations on gene expression in aldosterone-producing adenomas and adrenocortical cells[J]. J Clin Endocrinol Metab, 2012, 97:E1567-E1572.
[6]	Oki K, Gomez-Sanchez CE. The landscape of molecular mechanism for aldosterone production in aldosterone-producing adenoma[J]. Endocr J, 2020, 67:989-995.
[7]	Prakriya M. Calcium and cell function[J]. J Physiol, 2020, 598:1647-1648.
[8]	Williams TA, Monticone S, Crudo V, et al. Visinin-like 1 is upregulated in aldosterone-producing adenomas with KCNJ5 mutations and protects from calcium-induced apoptosis[J]. Hypertension, 2012, 59:833-839.
[9]	Su H, Gu Y, Li F, et al. The PI3K/AKT/mTOR signaling pathway is overactivated in primary aldosteronism[J]. PLoS One, 2013, 8:e62399. doi:10.1371/journal.pone.0062399
[10]	Williams TA, Monticone S, Morello F, et al. Teratocarcinoma-derived growth factor-1 is upregulated in aldosterone-producing adenomas and increases aldosterone secretion and inhibits apoptosis in vitro[J]. Hypertension, 2010, 55:1468-1475.
[11]	Backman S, Åkerström T, Maharjan R, et al. RNA Sequencing provides novel insights into the transcriptome of aldosterone producing adenomas[J]. Sci Rep, 2019, 9:6269. doi:10.1038/s41598-019-41525-2.
[12]	Lefèvre L, Omeiri H, Drougat L, et al. Combined transcriptome studies identify AFF3 as a mediator of the oncogenic effects of β-catenin in adrenocortical carcinoma[J]. Oncogenesis, 2015, 4:e161. doi:10.1038/oncsis.2015.20.
[13]	Oki K, Plonczynski MW, Gomez-Sanchez EP, et al. YPEL4 modulates HAC15 adrenal cell proliferation and is associated with tumor diameter[J]. Mol Cell Endocrinol, 2016, 434:93-98.
[14]	Shaikh LH, Zhou J, Teo AE, et al. LGR5 activates noncanonical wnt signaling and inhibits aldosterone production in the human adrenal[J]. J Clin Endocrinol Metab, 2015, 100:E836-E844.
[15]	Maniero C, Garg S, Zhao W, et al. NEFM (Neurofila-ment Medium) polypeptide, a marker for zona glomeru-losa cells in human adrenal, inhibits D1R (dopamine D1 receptor)-mediated secretion of aldosterone[J]. Hypertension, 2017, 70:357-364.
[16]	El Zein RM, Soria AH, Golib Dzib JF, et al. Retinoic acid receptor α as a novel contributor to adrenal cortex structure and function through interactions with wnt and vegfa signalling[J]. Sci Rep, 2019, 9:14677. doi:10.1038/s41598-019-50988-2.
[17]	Belavgeni A, Bornstein SR, von Mássenhausen A, et al. Exquisite sensitivity of adrenocortical carcinomas to induction of ferroptosis[J]. Proc Natl Acad Sci U S A, 2019, 116:22269-22274.
[18]	Yang Y, Tetti M, Vohra T, et al. BEX1 is differentially expressed in aldosterone-producing adenomas and protects human adrenocortical cells from ferroptosis[J]. Hypertension, 2021, 77:1647-1658.
[19]	Gong S, Tetti M, Reincke M, et al. Primary aldosteronism: metabolic reprogramming and the pathogenesis of aldosterone-producing adenomas[J]. Cancers (Basel), 2021, 13. doi:10.3390/cancers13153716.
[20]	Murakami M, Yoshimoto T, Nakabayashi K, et al. Integration of transcriptome and methylome analysis of aldosterone-producing adenomas[J]. Eur J Endocrinol, 2015, 173:185-195.
[21]	He J, Cao Y, Su T, et al. Downregulation of miR-375 in aldosterone-producing adenomas promotes tumour cell growth via MTDH[J]. Clin Endocrinol (Oxf), 2015, 83:581-589.
[22]	Peng KY, Chang HM, Lin YF, et al. miRNA-203 modulates qldosterone levels and cell proliferation by targeting wnt5a in aldosterone-producing adenomas[J]. J Clin Endocrinol Metab, 2018, 103:3737-3747.
[23]	Zhang G, Zou X, Liu Q, et al. MiR-193a-3p functions as a tumour suppressor in human aldosterone-producing adrenocortical adenoma by down-regulating CYP11B2[J]. Int J Exp Pathol, 2018, 99:77-86.
[24]	Fu R, Walters K, Kaufman ML, et al. In situ spatial reconstruction of distinct normal and pathological cell populations within the human adrenal gland[J]. J Endocr Soc, 2023, 7:bvad131. doi:10.1210/jendso/bvad131.
[25]	Motomura N, Yamazaki Y, Gao X, et al. Visualization of calcium channel blockers in human adrenal tissues and their possible effects on steroidogenesis in the patients with primary aldosteronism (PA)[J]. J Steroid Biochem Mol Biol, 2022, 218:106062. doi:10.1016/j.jsbmb.2022.106062.